Premium
IC–P–104: Imaging biomarkers to monitor treatment effects for Alzheimer's disease trials: The Alzheimer's disease imaging initiative
Author(s) -
Weiner Michael W.,
Thal Leon J.,
Petersen Ronald C.,
Jack Clifford R.,
Jagust William,
Trojanowski John Q.,
Beckett Laurel A.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.2310
Subject(s) - neuroimaging , clinical trial , alzheimer's disease neuroimaging initiative , disease , biomarker , medicine , alzheimer's disease , neurodegeneration , cognition , imaging biomarker , positron emission tomography , magnetic resonance imaging , oncology , medical physics , neuroscience , pathology , psychology , nuclear medicine , radiology , psychiatry , biology , biochemistry
were only partially modified after controlling for age (nondemented partial correlation coefficient 0.41, p 0.026; early AD r -0.39, p 0.06). There was no apparent relationship between VO2 peak and hippocampal volume or white matter lesion burden. We performed a median split on both groups for VO2 . Those with lower VO2 peak had lower whole brain volume (p 0.05) in ANCOVA analysis controlling for age. A dementia status by VO2 peak interaction was present (p 0.04) before and after controlling for age suggesting the relationship between VO2 peak and brain atrophy was attenuated by the presence of dementia. Conclusion: Enhanced fitness may protect against age-related brain atrophy in nondemented individuals but is not associated with atrophy in early AD.